AIPL1: A Potential Drug Target and Biomarker (G23746)

Target Name: AIPL1

NCBI ID: G23746

AIPL1

AIPL1: A Potential Drug Target and Biomarker

AIPL1 (Aryl-hydrocarbon-interacting protein-like 1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique function as an interaction protein with aryl hydrocarbons (AHCs) has led to a significant impact in the field of pharmacology. In this article, we will discuss the molecular mechanisms of AIPL1, its potential drug targets, and its potential as a biomarker for various diseases.

Molecular Mechanisms of AIPL1

AIPL1 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and gastrointestinal tract. It is composed of a unique transmembrane domain, a cytoplasmic tail, and an N-terminus that contains a glycophosphorylated residue. The transmembrane domain of AIPL1 is responsible for its unique interaction with AHCs, which are naturally occurring molecules that are found in various cellular compartments.

The cytoplasmic tail of AIPL1 is composed of a unique farnesylated cysteine residue, which is involved in the regulation of protein stability and localization to the plasma membrane. The N-terminus of AIPL1 contains a glycophosphorylated residue that is involved in protein-protein interactions and may play a role in AIPL1's stability and localization to the plasma membrane.

Potential Drug Targets

AIPL1 has been identified as a potential drug target for various diseases due to its unique interaction with AHCs. One of the primary drug targets for AIPL1 is the regulation of cell growth and differentiation. AIPL1 has been shown to play a role in the regulation of cell proliferation and has been shown to interact with various transcription factors, including NF-kappa-B, p53, and HIF1伪.

In addition to its role in cell growth and differentiation, AIPL1 has also been shown to play a role in the regulation of cell survival. AIPL1 has been shown to interact with various stress response pathways, including the DNA damage response pathway, and has been shown to play a role in the regulation of DNA repair.

Potential Biomarkers

AIPL1 has also been identified as a potential biomarker for various diseases due to its unique interaction with AHCs. One of the primary biomarkers for AIPL1 is the level of AIPL1 expression in various tissues, including cancer, neurodegenerative disorders, and autoimmune diseases. AIPL1 has also been shown to play a role in the regulation of inflammation and has been shown to interact with various inflammatory cytokines, including TNF-伪 and IL-1尾.

In addition to its role in inflammation, AIPL1 has also been shown to play a role in the regulation of pain perception. AIPL1 has been shown to interact with various pain modulators, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), and has been shown to play a role in the regulation of pain perception.

Conclusion

In conclusion, AIPL1 is a protein that has significant impact in the field of pharmacology due to its unique interaction with AHCs. Its potential as a drug target and biomarker for various diseases makes it an attractive target for future research. Further studies are needed to fully understand the molecular mechanisms of AIPL1 and its potential as a drug and biomarker.

Protein Name: Aryl Hydrocarbon Receptor Interacting Protein Like 1

Functions: May be important in protein trafficking and/or protein folding and stabilization

The "AIPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AIPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets